Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SELTS:0RAR +0.20%71 3-Year EBITDA Growth Rate is -16.40% as of Jun. 2026. GuruFocus rates LTS:0RAR with a GF Score™ of 71/100 and a GF Value™ of €29.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Stratec SE ranks worse than 84.3% on this metric.
During the past 12 months, Stratec SE's average EBITDA Per Share Growth Rate was -23.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -16.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -10.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Stratec SE was 116.80% per year. The lowest was -25.70% per year. And the median was 7.90% per year.
Stratec SE (LTS:0RAR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Stratec SE 3-Year EBITDA Growth Rate Related Terms
LTS:0RAR vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Stratec SE's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Stratec SE's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -16.40% mean?
Stratec SE (LTS:0RAR) has a 3-Year EBITDA Growth Rate of -16.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stratec SE and its competitors. According to the industry distribution chart, Stratec SE ranks #580 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 84.3%.
Is Stratec SE's 3-Year EBITDA Growth Rate too high?
Stratec SE's current 3-Year EBITDA Growth Rate is -16.40%. Based on the distribution chart, Stratec SE ranks #580 out of 688 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stratec SE has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #580 out of 688 companies for 3-Year EBITDA Growth Rate. This places Stratec SE in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current 3-Year EBITDA Growth Rate is -16.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (LTS:0RAR) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.99, compared to a current price of €24.45 — trading 18.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -16.40%. Stratec SE's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Stratec SE (LTS:0RAR), the current 3-Year EBITDA Growth Rate is -16.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (LTS:0RAR) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €24.45 is trading 18.5% below its estimated GF Value™ of €29.99.
GuruFocus considers Stratec SE to be Modestly Undervalued.
Key valuation signals for LTS:0RAR:
3-Year EBITDA Growth Rate: -16.40%
GF Value™: €29.99 vs. price of €24.45 (18.5% below fair value)
No single metric tells the full story. See the LTS:0RAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
71GF Score
Get the complete analysis for LTS:0RAR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAR has been successfully added to your 
